Interferon-alpha Induced and Ribavirin induced thyroid dysfunction in patients with chronic hepatitis C

Hepatitis Monthly

Volumn 10, Issue 2, 2010, Pages 132-140

  Nadeem, Amina ^a   Hussain, Muhammad Mazhar ^a   Aslam, Muhammad ^b   Hussain, Tassawar ^c  

^a ARMY MEDICAL COLLEGE   (Pakistan)

^b SHIFA COLLEGE OF MEDICINE   (Pakistan)

^c Hearts International Hospital   (Pakistan)

Author keywords

Chronic hepatitis C; Interferon; Ribavirin; Thyroid disease

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PEGINTERFERON; RADIOACTIVE IODINE; RIBAVIRIN; THYROID ANTIBODY; THYROXINE;

ANTIBODY DETECTION; CLINICAL FEATURE; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG MECHANISM; GRAVES DISEASE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MENTAL DISEASE; PATHOGENESIS; PREDICTION; PREVALENCE; RECOMMENDED DRUG DOSE; REVIEW; SEX DIFFERENCE; THYROID DISEASE; THYROID FUNCTION TEST; TREATMENT RESPONSE;

EID: 77954884063     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. World Health Organization. Hepatitis C. Fact sheet Number 164, revised October 2000. Available from: http://www.who.int/mediacentre/factsheets/fs164/en.
2. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450-6.
3. Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North A=m. 2007;36(4):1051-66; x-xi.
4. Foldes I, David K, Horvath G, Osztrogonacz H, Jankovics K, Tolvaj G. [Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha]. Orv Hetil. 2004;145(23):1211-6.
5. Murdolo G, Francisci D, Forini F, et al. Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-alpha therapy. J Endocrinol Invest. 2002;25(11):938-46.
6. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13(6):547-51.
7. Tarantino G, Gagliardi G, Conca P. Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?. Int J Immunopathol Pharmacol. 2008;21(2):467-9.
8. Wong V, Fu AX, George J, Cheung NW. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis Clin Endocrinol (Oxf). 2002;56(6):793-8.
9. Mazziotti G, Sorvillo F, Stornaiuolo G, et al. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study. J Endocrinol Invest. 2002;25(7):624-30.
10. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002;146(6):743-9.
11. Morisco F, Mazziotti G, Rotondi M, et al. Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C. Dig Liver Dis. 2001;33(3):247-53.
12. Nagane Y, Utsugisawa K, Kizawa H, Kondoh R, Terayama Y. [Hypothyroid myopathy caused by interferon-alpha therapy for chronic hepatitis C]. Rinsho Shinkeigaku. 2005;45(6):441-4.
13. Lloyd AR, Jagger E, Post JJ, et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol. 2007;85(1):24-32.
14. Bini EJ, Mehandru S. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Arch Intern Med. 2004;164(21):2371-6.
15. Doi F, Kakizaki S, Takagi H, et al. Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005;25(2):242-6.
16. Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat. 2009;16(3):168-77.
17. Gelu-Simeon M, Burlaud A, Young J, Pelletier G, Buffet C. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World J Gastroenterol. 2009;15(3):328-33.
18. Huang JF, Chuang WL, Dai CY, et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat. 2006;13(6):396-401.
19. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol. 2006;21(1 Pt 2):319-26.
20. Masood N, Ghori R, Memon A, et al. Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. J Coll Physicians Surg Pak. 2008;18(6):347-51.
21. Moncoucy X, Leymarie F, Delemer B, et al. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C. Gastroenterol Clin Biol. 2005;29(4):339-45.
22. Nadeem A, Aslam M, Khan DA, Hussain T, Khan SA. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. J Coll Physicians Surg Pak. 2009;19(2):86-9.
23. Ziaee A, Esfehanian F, Alavian S, Sarreshtedari M. Thyroid Dysfunction in Patients with Chronic Viral Hepatitis B and C during Alpha Interferon Therapy. Hepat Mon. 2009;9(2):110-3.
24. Parana R, Cruz M, Santos-Jesus R, Ferreira K, Codes L, Cruz T. Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. Braz J Infect Dis. 2000;4(6):284-90.
25. Surla G, Mahler R, Jacobson IM. Thyroid dysfunction in patients with chronic hepatitis C treatment with interferon alpha. Am J Gastroenterol. 2000;95(9):2520.
26. Ward DL, Bing-You RG. Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: screening and monitoring recommendations. Endocr Pract. 2001;7(1):52-8.
27. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F, et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158(13):1445-8.
28. Tomer Y. Hepatitis C and interferon induced thyroiditis. J Autoimmun. 2009. [in press].
29. Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med. 2004;117(1):10-3.
30. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251(5):400-6.
31. Tran HA, Reeves GE, Jones TL. The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM. 2009;102(2):117-22.
32. Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43(4):661-72.
33. Indolfi G, Stagi S, Bartolini E, et al. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf). 2008;68(1):117-21.
34. Castellano Higuera A, Gonzales Reimers E, Alarco Hernandez B, Santolaria Fernandez F, Rodriguez Gaspar M. [Hypothyroidism, hemolytic anemia and cryoglobulinemia in a patient with hepatitis C virus infection: efficacy of treatment with alpha-interferon]. An Med Interna. 2003;20(7):391-2.
35. Andrade LJ, Atta AM, D'Almeida Junior A, Parana R. Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin--a review. Braz J Infect Dis. 2008;12(2):144-8.
36. Pouthier D, Theissen F, Humbel RL. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient. Nephrol Dial Transplant. 2002;17(1):174.
37. Rocco A, Gargano S, Provenzano A, et al. Incidence of autoimmune thyroiditis in interferon-alpha treated and untreated patients with chronic hepatitis C virus infection. Neuro Endocrinol Lett. 2001;22(1):39-44.
38. El-Kady IM. Assessment of humoral immune response in patients with chronic hepatitis C virus infection. Egypt J Immunol. 2004;11(2):141-7.
39. Shen L, Bui C, Mansberg R, Nguyen D, Alam-Fotias S. Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C. Clin Nucl Med. 2005;30(8):546-7.
40. Schiemann U, Walli R, Schmidt F, Bogner J, Gross M. Thyroid hypoechogenicity in patients with chronic hepatitis receiving interferon-alpha therapy: evaluation by standardized grey scale ultrasonography. Eur J Med Res. 2002;7(6):271-7.
41. Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol. 2009;24(7):1163-8.
42. Ridruejo E, Christensen AF, Mando OG. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J Gastroenterol Hepatol. 2006;18(6):693-4.
43. Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol. 1999;14(5):419-22.
44. Braga-Basaria M, Basaria S. Interferon-alpha-induced transient severe hypothyroidism in a patient with Graves' disease. J Endocrinol Invest. 2003;26(3):261-4.
45. Carella C, Mazziotti G, Morisco F, et al. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86(5):1925-9.
46. McEvoy GK, Litvak K, Welsh OH. The frequency of non-organ-specific autoantibodies in patients with chronic hepatitis C and its relation with disease severity and response to therapy. Iran J Clin Infect Dis. 2006;1(1):5-10.